Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. Breast Cancer Res Treat. 2019 Jun; 175(2):297-303.